report that the immuno‐effect of the CD42 inhibitor outweighs any tumor cell‐intrinsic effect, it has also been reported that a low level CDC42 in the serum can predict the clinical response to ICI in patients with advanced hepatocellular carcinoma (HCC) [5] and advanced cervical cancer [6]. The gene discussed is CDC42; the disease is neoplasm.